Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
TheFly reported on June 24 that Raymond James initiated coverage of MPLT with a Strong Buy rating and a $46 price target.
Maplight Therapeutics Inc. (MPLT)
Market is closed
Sector: Healthcare
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.00 | 1,000,000 | $13,000,000.00 | 20,906,689 | 2026-07-30 | Filing | |
| $12.63 | 3,000 | $37,890.00 | 19,906,689 | 2026-07-29 | Filing | |
| $11.69 | 65,137 | $761,392.91 | 19,903,689 | 2026-07-28 | Filing | |
| $10.74 | 141,088 | $1,515,510.86 | 19,838,552 | 2026-07-28 | Filing | |
| $9.52 | 15,620 | $148,702.40 | 15,620 | 2026-07-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.54 | 22,082 | $276,908.28 | 202,380 | 2026-08-03 | Filing | |
| $38.17 | 900 | $34,353.00 | 144,240 | 2026-07-17 | Filing | |
| $37.61 | 16,969 | $638,204.09 | 145,140 | 2026-07-17 | Filing | |
| $36.51 | 600 | $21,906.00 | 162,109 | 2026-07-17 | Filing | |
| $37.44 | 1,476 | $55,261.44 | 162,709 | 2026-07-16 | Filing |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
8 Must-Buy Small Cap Stocks to Buy
After many years of large capitalization companies dominating the US equities market, time is ripe for rotation.
8 Healthcare Stocks Insiders Are Buying
Insider buying tends to draw attention because insiders know their companies best.
Hedge Fund Resource Center